China’s biotechnology market has “significantly” driven up the demand for primate experimental models as the market recovers, tightening the supply of laboratory monkeys, according to a leading biotech firm. The continued recovery of fundraising and out-licensing deals in innovative drugs in China this year has led…

Read the full story at South China Morning Post →